A Phase 1/2, First-in-Human, Double-Masked, Placebo-Controlled, Dose-Escalation Study Evaluating the Safety, Tolerability, and Efficacy of RU-101 Ophthalmic Solution in Patients With Severe Dry Eye
Objectives: Primary To determine the safety and tolerability of escalating doses of RU-101 for 4 weeks in patients with severe dry eye Secondary To explore the efficacy of RU-101 To explore optimal endpoints for future studies
Phase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period
This study is a multicenter trial performed in Japan, consisting of a comparative study period and a continuous administration period. Effect of 0.15% UF-021 eye drops on improvement in central retinal sensitivity with HFA will be verified in 52 weeks comparative study period by a placebo-controlled, double-masked study in patients with retinitis pigmentosa. The safety of same eye drops will also be examined in 52 weeks continuous administration period, in all the patients who completed the comparative study period.
Phase I randomized study of 0.15% UF-021 in patients with geographic atrophy treated after wet age-related macular degeneration - Phase I Study of 0.15% UF-021 in patients with geographic atrophy treated after wet AMD
Here, the authors examined a neuroprotective effect of iso-Pr unoprostone in vitro using a rat model of local ischemic reperfusion. The results demonstrated the neuroprotective effect of iso-Pr unoprostone for post-ischemic reperfusion.
100 Deals associated with R-Tech Ueno, Ltd.
Login to view more data
100 Translational Medicine associated with R-Tech Ueno, Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.